Phosphorus Solution 1.2mmol/L

Adult dosage

The fluid replacement rate for blood filtration and dialysis is 500-3000 mL/h. The flow rate of dialysate for continuous blood dialysis and continuous blood filtration is 500-2500 mL/h. The typical total integrated flow rate in adults undergoing continuous renal replacement therapy (for dialysate and fluid replacement) is about 2000-2500 mL/h, which corresponds to a daily fluid replacement volume of approximately 48-60L.

Children's dosage

The fluid replacement rate for blood filtration and dialysis is 15-35 mL/kg/h. The flow rate of dialysate for continuous blood dialysis and continuous blood filtration is 15-30 mL/kg/h.

This medication should not be administered to certain patients. For instance, it must not be used in patients allergic to it or those with hyperkalemia (high blood potassium levels). It should also be avoided in patients with metabolic alkalosis, hyperphosphatemia, and those in acute renal failure where uremia is not improved by blood filtration or dialysis. Caution is required for patients with insufficient arterial pressure during vascular access or those with high bleeding risk during systemic anticoagulation therapy. This medication should be used under the guidance and supervision of a physician experienced in blood filtration or dialysis treatment, and the prescribed dosage must be strictly followed. During treatment, the patient's hemodynamic status, fluid balance, electrolytes, and acid-base balance must be closely monitored. This medication contains potassium and phosphate, which can temporarily cause hyperkalemia or hyperphosphatemia, thus the infusion rate must be adjusted and blood levels monitored. If hyperkalemia or hyperphosphatemia do not improve, administration should be discontinued immediately. Patients with fluid imbalance (e.g., heart failure or intracranial hemorrhage) should be carefully monitored for clinical status. Additionally, since this medication does not contain glucose, hypoglycemia may occur, and patients with diabetes should regularly check their blood glucose levels. This medication can interact with other drugs, so when used in conjunction with phosphate-containing IV fluids or preparations with vitamin D and calcium, there may be an increased risk of hyperphosphatemia or hypercalcemia. Furthermore, during blood filtration or dialysis, drug concentrations may vary, requiring corrective treatment if necessary. There is insufficient clinical data on the safety of this medication in pregnant or breastfeeding patients, thus it should only be used when absolutely necessary. In the case of overdose, fluid overload, electrolyte imbalances, and acid-base imbalances may occur, necessitating monitoring and appropriate blood filtration or dialysis treatment by trained healthcare professionals. If metabolic acidosis or hyperphosphatemia occurs due to overdose, administration must be stopped immediately. This medication can be warmed to 37 degrees Celsius before use, but should not be heated in a microwave or directly in water. If the packaging is damaged or the solution is not clear, it should not be used, and strict aseptic handling is required before and after use to maintain sterility. Any remaining solution after use should be discarded, and it is for single use only. Store between 4 to 30 degrees Celsius, avoiding refrigeration or freezing. Use as soon as possible after mixing, and do not store at room temperature for more than 24 hours.

Mild side effects

• Electrolyte imbalance
• fluid imbalance
• acid-base imbalance
• hypotension
• nausea
• vomiting
• muscle cramps

This medication should be stored in a sealed container to avoid exposure to air or moisture. It is recommended to maintain a storage temperature between 4 to 30 degrees Celsius. Proper storage helps to maintain the drug's efficacy and safety for a longer duration.

Appearance

A colorless, transparent liquid contained in a colorless, transparent plastic bag, separated into two spaces by one partition.

Package unit

5000ml/bag